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background:  Recent studies using ATP III guidelines show that peripheral artery disease (PAD) patients have less optimal lipid control 
compared to those with coronary artery disease (CAD). Our study aimed to compare lipid management in patients with PAD, CAD and 
CAD with PAD by applying the new 2013 guidelines.
Methods:  A retrospective chart review of patients with CAD and PAD seen at our institution between Jan 2009 to March 2012 was 
performed. Demographic data, lipid levels and statin use information were obtained. Based on the new guidelines we classified statin 
therapy into high, moderate and low intensity therapy.
Results:  There were a total of 11134 subjects. Average age was 69±11 yrs, 35% were women, and 33% had diabetes. Patients with PAD 
had significantly higher total cholesterol, LDL and triglycerides compared to patients with CAD (Table 1A). While 76% of PAD patients were 
on statin therapy compared to a 100% of CAD patients (p <0.001), only 178 PAD patients (30%) achieved a LDL goal of <70 mg/dl and 
371 PAD patients (62%) achieved a LDL goal of <100 mg/dl. Application of the new guidelines showed that PAD patients were significantly 
undertreated compared to CAD groups, especially in patients aged ≤75 years (Table 1B).
conclusion:  Application of new guidelines showed that PAD patients have significantly less guideline recommended lipid treatment 
compared with those with CAD and CAD with PAD. Physicians need to be more aggressive with lipid control in patients with PAD.
Table 1A: Comparison of lipid control among CAD, PAD and CAD and PAD groups
Lipid Control Age 75 years Age > 75 years
CAD PAD CAD + PAD P Value (ANOVA) CAD PAD CAD + PAD
P Value 
(ANOVA)
Total Cholesterol 153 ± 41 165 ± 44 151 ± 44 < 0.001 146±36 160±41 143±36 < 0.001
LDL Cholesterol 85 ± 34 94 ± 37 83 ± 32 0.001 77±29 89±33 76±28 0.002
HDL Cholesterol 44 ± 15 45 ± 16 42 ± 15 < 0.001 48±15 49±16 45±15 < 0.001
Triglycerides 136 ± 100 146 ± 96 145 ± 135 0.03 112±62 114±60 122±67 0.01
LDL <70mg/dl 2449 (36.8%)
107 
(28.1%)
216 
(36.7%) 0.003 (Chi Sq)
1294 
(44.6%) 71 (33%)
188 
(48.6%) 0.001 (Chi Sq)
LDL <100 md/dl 4994 (75%) 228 (59.8%)
449 
(76.4%)
< 0.001 (Chi 
Sq)
2426 
(83.5%)
143 
(66.5%)
319 
(82.4%)
< 0.001 (Chi 
Sq)
Table 1B: Differences in statin therapy among CAD, PAD and CAD + PAD groups
Intensity of Therapy Age 75 years Age > 75 years
CAD PAD CAD + PAD P Value (Chi Sq) CAD PAD CAD + PAD
P Value (Chi 
Sq)
High 2560 (38.4 %) 50 (13.1%) 241 (41%) < 0.001
743 
(25.6%) 28 (13%) 89 (23%) < 0.001
Moderate 3585 (53.8%)
193 
(50.7%)
266 
(45.2%) < 0.001
1822 
(62.7%) 116 (54%)
208 
(53.7%) < 0.001
Low 414 (6.2%) 27 (7.1%) 25 (4.3%) < 0.001 293 (10.1%) 28 (13%) 39 (10.1%) < 0.001
None or missing 
dose information 100 (1.5%) 111 (29.1%) 56 (9.5%) < 0.001 46 (1.6%) 43 (20%) 51 (13.2%) < 0.001
